← Leaderboards
Daniel Bondeson
Yale University
$452,479
Attributed
$452,479
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $101K · FY2016–21$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$452,479 · 2
By mechanism
K00$363,359 · 1
F99$89,120 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Craig M Crews$33,790,660
- Anthony J Koleske$16,724,381
- Lucila Ohno-Machado$130,482,087
- Richard P Lifton$24,984,883
- Mark Bender Gerstein$57,665,883
Others in their field
Top investigators on “High Throughput Screening”
- Richard A Gibbs · Baylor College Of Medicine$250,166,309
- Leonard Freedman · Leidos Biomedical Research, Inc.$249,633,249
- David Heimbrook · Leidos Biomedical Research, Inc.$181,270,700
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,111,713
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
Research focus
High Throughput ScreeningImmuneAnimal ModelBiochemicalBiochemical PathwayAdvanced DevelopmentBindingBiologyBiophysical PropertiesCancer BiologyCell Culture TechniquesCell ProliferationCellsBaseComplexBiological SystemsDesignDoseDown-RegulationFailureFluorescence PolarizationGenerationsGenetic ManipulationInsight
Grant awards (6)
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$101,003
K00 · FY2021 · CA · contact PI
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$96,388
K00 · FY2020 · CA · contact PI
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$91,772
K00 · FY2019 · CA · contact PI
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$74,196
K00 · FY2018 · CA · contact PI
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$44,044
F99 · FY2017 · CA · contact PI
Investigating degradation as a therapeutic strategy against the Pseudo-kinase KSR$45,076
F99 · FY2016 · CA · contact PI